Investor Calendar Invites You to the Capricor Therapeutics First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016
LOS ANGELES, CA / ACCESSWIRE / May 11, 2016 / Capricor Therapeutics, Inc. (CAPR) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 12, 2016 at 4:30 PM Eastern Time.
To participate in this event, dial 877-830-2629 domestically, or 785-424-1231 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=174994 or on the Capricor Therapeutics website (http://capricor.com/news/events/).
If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or http://capricor.com/news/events/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics. The Company's lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two lead product candidates under investigation: CAP-1002, a cardiac cell therapy, and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction, advanced heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as other potential indications. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information, visit www.capricor.com.
SOURCE: Investor Calendar
